OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Pulmonary Medicine is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors	93
Endotypes and phenotypes in obstructive sleep apnea	71
Chronic obstructive pulmonary disease and COVID-19: interrelationships	44
Pulmonary pathology of COVID-19: a review of autopsy studies	44
Transmission of respiratory tract infections at mass gathering events	35
Editorial: The explosive epidemic outbreak of novel coronavirus disease 2019 (COVID-19) and the persistent threat of respiratory tract infectious diseases to global health security	32
ABCA3 mutations in adult pulmonary fibrosis patients: a case series and review of literature	31
Recent advances in rheumatoid arthritis-associated interstitial lung disease	31
Viral respiratory infections: a cause of community-acquired pneumonia or a predisposing factor?	30
A clinical review of long-COVID with a focus on the respiratory system	27
COVID-19: vaccines, efficacy and effects on variants	24
MicroRNAs: future biomarkers and targets of therapy in asthma?	24
Obstructive sleep apnea and cancer: a complex relationship	21
New guidelines for severe community-acquired pneumonia	20
Drug-induced sarcoidosis-like reactions	20
Socioeconomic determinants and disparities in sarcoidosis	19
A contemporary review of radiation pneumonitis	18
Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies	18
Update in adult community-acquired pneumonia: key points from the new American Thoracic Society/Infectious Diseases Society of America 2019 guideline	18
Genetics in sarcoidosis	17
The role of computed tomography scan in the diagnosis of COVID-19 pneumonia	17
Does gender matter: sex-specific aspects of symptoms, outcome, and therapy of obstructive sleep apnea	17
Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world – opportunities and challenges	17
Diabetes, insulin resistance, and asthma: a review of potential links	17
Asthma and severe acute respiratory syndrome coronavirus 2019: current evidence and knowledge gaps	16

Upper airway muscles: influence on obstructive sleep apnoea pathophysiology and pharmacological and technical treatment options	16
Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment	16
Monitoring early stage lung disease in cystic fibrosis	16
An update on sarcoidosis-associated pulmonary hypertension	16
Sarcoidosis and autoimmunity	16
TBX4 variants and pulmonary diseases: getting out of the ‘Box’	16
The impact of fungal allergic sensitization on asthma	16
Pleuroparenchymal fibroelastosis	15
Telehealth and virtual health monitoring in cystic fibrosis	15
ICU preparedness in pandemics: lessons learned from the coronavirus disease-2019 outbreak	15
Risk stratification of indeterminate pulmonary nodules	14
Opioids and sleep	14
Update on sarcoidosis guidelines	14
Insights into pathogenesis and clinical implications in myositis-associated interstitial lung diseases	14
Obstructive sleep apnea in pulmonary fibrosis	14
Impact of obesity on pulmonary function: current understanding and knowledge gaps	14
COVID-19: a new burden of respiratory disease among South African miners?	14
COVID-19 outcomes in people with cystic fibrosis	14
Advances in the epidemiology, clinical features, diagnosis, clinical management and prevention of coronavirus disease 2019	13
COVID-19 and other respiratory tract infections at mass gathering religious and sporting events	13
Revisiting matrix metalloproteinase 12: its role in pathophysiology of asthma and related pulmonary diseases	13
Drug treatment of COVID-19 infection	13
Pneumococcal virulence factors in community-acquired pneumonia	13
The other connective tissue disease-associated interstitial lung diseases: Sjogren's syndrome, mixed connective tissue disease, and systemic lupus erythematosus	13
Pulmonary rehabilitation in a postcoronavirus disease 2019 world: feasibility, challenges, and solutions	12
New pharmacologic agents for insomnia and hypersomnia	12
Nontuberculous mycobacteria in cystic fibrosis	12
COVID-19 new diagnostics development: novel detection methods for SARS-CoV-2 infection and considerations for their translation to routine use	11
Recent advances in sarcoidosis genomics: epigenetics, gene expression, and gene by environment (G × E) interaction studies	11
Role of antioxidants in the treatment of gastroesophageal reflux disease-associated idiopathic pulmonary fibrosis	11
The role of PET in the management of sarcoidosis	11
Treatment of pulmonary exacerbations in cystic fibrosis	11
SMART - is it practical in the United States?	11
Advances in molecular diagnostic tests for pneumonia	11
Severe pulmonary toxicity associated with inhalation of pyrethroid-based domestic insecticides (Bop/Sapolio): a case series and literature review	11
Epidemiology and real-life experience in progressive pulmonary fibrosis	11
Critical care of patients with pulmonary arterial hypertension	11
Respiratory and sleep-related complications of multiple system atrophy	11
The current understanding and future directions for sputum microbiome profiling in chronic obstructive pulmonary disease	11
Burden of idiopathic pulmonary fibrosis on patients’ emotional well being and quality of life: a literature review	11
Robotic bronchoscopy for peripheral pulmonary lesions: a convergence of technologies	10
Drug-resistant tuberculosis: advances in diagnosis and management	10
Obstructive lung diseases and allergic bronchopulmonary aspergillosis	10
Frailty in patients with interstitial lung disease	10
Pulmonary adverse events following immune checkpoint inhibitors	10
Implementation of digital home monitoring and management of respiratory disease	10
The evolving role of radiological imaging in cystic fibrosis	10
Immunology of sarcoidosis: old companions, new relationships	10
Atypical mycobacterial infections – management and when to treat	10
Advancing bacteriophages as a treatment of antibiotic-resistant bacterial pulmonary infections	10

Vaping epidemic in US teens: problem and solutions	10
Looking into the future of sarcoidosis: what is next for treatment?	10
Unprecedented: the toxic synergism of Covid-19 and climate change	10
Robotic bronchoscopy and future directions of interventional pulmonology	10
Telehealth in chronic obstructive pulmonary disease: before, during, and after the coronavirus disease 2019 pandemic	10
Influenza: clinical aspects, diagnosis, and treatment	9
At a crossroads: coronavirus disease 2019 recovery and the risk of pulmonary vascular disease	9
Beyond antibiotics for pulmonary nontuberculous mycobacterial disease	9
Beta-blockers in chronic obstructive pulmonary disease: the good, the bad and the ugly	9
Lung microbiome, gut–lung axis and chronic obstructive pulmonary disease	9
Biopsy in interstitial lung disease: specific diagnosis and the identification of the progressive fibrotic phenotype	9
Rapid eye movement predominant obstructive sleep apnoea: prognostic relevance and clinical approach	9
Current practices in the management of central airway obstruction	9
Advanced pulmonary sarcoidosis	9
Pneumonitis associated with immune checkpoint inhibitors among patients with non-small cell lung cancer	9
Hit-hard and early versus step-up treatment in severe sarcoidosis	9
Human global and population-specific genetic susceptibility to Mycobacterium tuberculosis infection and disease	9
Drug-induced sleep endoscopy: techniques, interpretation and implications	9
Lethal zoonotic coronavirus infections of humans – comparative phylogenetics, epidemiology, transmission, and clinical features of coronavirus disease 2019, The Middle East respiratory syndrome and se	8
Pulmonary hypertension in majority countries: opportunities amidst challenges	8
COVID-19 – pathogenesis and immunological findings across the clinical manifestation spectrum	8
Chronic obstructive pulmonary disease risk assessment tools: is one better than the others?	8
Experimental models of sarcoidosis: where are we now?	8
Alternative algorithms and devices in sleep apnoea diagnosis: what we know and what we expect	8
Pulmonary toxicity associated with occupational and environmental exposure to pesticides and herbicides	8
Bronchoscopic diagnosis of peripheral lung lesions	8
The justification for the progressive fibrotic phenotype	8